vs
Apellis Pharmaceuticals, Inc.（APLS）与Stock Yards Bancorp, Inc.（SYBT）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Stock Yards Bancorp, Inc.的1.9倍（$199.9M vs $104.4M），Stock Yards Bancorp, Inc.净利率更高（35.1% vs -29.5%，领先64.6%），Stock Yards Bancorp, Inc.同比增速更快（11.7% vs -5.9%），Stock Yards Bancorp, Inc.自由现金流更多（$154.0M vs $-14.3M），过去两年Stock Yards Bancorp, Inc.的营收复合增速更高（11.9% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Stock Yards Bancorp是美国的区域银行控股企业，前身为1903年成立的派克维尔国民银行，总部仍位于肯塔基州阿巴拉契亚核心地带的派克维尔。旗下运营商业银行业务主体Community Trust Bank，以及位于列克星敦的信托机构Community Trust and Investment Company。
APLS vs SYBT — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $104.4M |
| 净利润 | $-59.0M | $36.6M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 45.9% |
| 净利率 | -29.5% | 35.1% |
| 营收同比 | -5.9% | 11.7% |
| 净利润同比 | -62.2% | 15.5% |
| 每股收益（稀释后） | $-0.40 | $1.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $104.4M | ||
| Q3 25 | $458.6M | $101.5M | ||
| Q2 25 | $178.5M | $97.8M | ||
| Q1 25 | $166.8M | $93.5M | ||
| Q4 24 | $212.5M | $93.5M | ||
| Q3 24 | $196.8M | $89.8M | ||
| Q2 24 | $199.7M | $85.7M | ||
| Q1 24 | $172.3M | $83.3M |
| Q4 25 | $-59.0M | $36.6M | ||
| Q3 25 | $215.7M | $36.2M | ||
| Q2 25 | $-42.2M | $34.0M | ||
| Q1 25 | $-92.2M | $33.3M | ||
| Q4 24 | $-36.4M | $31.7M | ||
| Q3 24 | $-57.4M | $29.4M | ||
| Q2 24 | $-37.7M | $27.6M | ||
| Q1 24 | $-66.4M | $25.9M |
| Q4 25 | -25.6% | 45.9% | ||
| Q3 25 | 48.7% | 45.0% | ||
| Q2 25 | -18.6% | 43.9% | ||
| Q1 25 | -50.0% | 44.5% | ||
| Q4 24 | -12.3% | 41.9% | ||
| Q3 24 | -24.0% | 41.2% | ||
| Q2 24 | -14.7% | 41.2% | ||
| Q1 24 | -36.0% | 39.5% |
| Q4 25 | -29.5% | 35.1% | ||
| Q3 25 | 47.0% | 35.7% | ||
| Q2 25 | -23.6% | 34.8% | ||
| Q1 25 | -55.3% | 35.6% | ||
| Q4 24 | -17.1% | 33.9% | ||
| Q3 24 | -29.2% | 32.7% | ||
| Q2 24 | -18.9% | 32.2% | ||
| Q1 24 | -38.5% | 31.1% |
| Q4 25 | $-0.40 | $1.24 | ||
| Q3 25 | $1.67 | $1.23 | ||
| Q2 25 | $-0.33 | $1.15 | ||
| Q1 25 | $-0.74 | $1.13 | ||
| Q4 24 | $-0.30 | $1.07 | ||
| Q3 24 | $-0.46 | $1.00 | ||
| Q2 24 | $-0.30 | $0.94 | ||
| Q1 24 | $-0.54 | $0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | $26.8M |
| 股东权益账面价值 | $370.1M | $1.1B |
| 总资产 | $1.1B | $9.5B |
| 负债/权益比越低杠杆越低 | — | 0.02× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — | ||
| Q1 24 | $325.9M | — |
| Q4 25 | — | $26.8M | ||
| Q3 25 | — | $26.8M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $26.8M | ||
| Q4 24 | — | $26.8M | ||
| Q3 24 | — | $26.8M | ||
| Q2 24 | — | $26.8M | ||
| Q1 24 | $93.1M | $26.8M |
| Q4 25 | $370.1M | $1.1B | ||
| Q3 25 | $401.2M | $1.0B | ||
| Q2 25 | $156.3M | $1.0B | ||
| Q1 25 | $164.2M | $975.5M | ||
| Q4 24 | $228.5M | $940.5M | ||
| Q3 24 | $237.1M | $934.1M | ||
| Q2 24 | $264.3M | $894.5M | ||
| Q1 24 | $266.7M | $874.7M |
| Q4 25 | $1.1B | $9.5B | ||
| Q3 25 | $1.1B | $9.3B | ||
| Q2 25 | $821.4M | $9.2B | ||
| Q1 25 | $807.3M | $9.0B | ||
| Q4 24 | $885.1M | $8.9B | ||
| Q3 24 | $901.9M | $8.4B | ||
| Q2 24 | $904.5M | $8.3B | ||
| Q1 24 | $831.9M | $8.1B |
| Q4 25 | — | 0.02× | ||
| Q3 25 | — | 0.03× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.03× | ||
| Q4 24 | — | 0.03× | ||
| Q3 24 | — | 0.03× | ||
| Q2 24 | — | 0.03× | ||
| Q1 24 | 0.35× | 0.03× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $166.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $154.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 147.5% |
| 资本支出强度资本支出/营收 | 0.1% | 11.5% |
| 现金转化率经营现金流/净利润 | — | 4.54× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $260.5M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $166.0M | ||
| Q3 25 | $108.5M | $38.2M | ||
| Q2 25 | $4.4M | $55.9M | ||
| Q1 25 | $-53.4M | $19.8M | ||
| Q4 24 | $19.4M | $142.9M | ||
| Q3 24 | $34.1M | $55.4M | ||
| Q2 24 | $-8.3M | $51.1M | ||
| Q1 24 | $-133.0M | $17.4M |
| Q4 25 | $-14.3M | $154.0M | ||
| Q3 25 | $108.3M | $35.2M | ||
| Q2 25 | $4.4M | $53.5M | ||
| Q1 25 | $-53.4M | $17.8M | ||
| Q4 24 | $19.3M | $133.0M | ||
| Q3 24 | — | $53.9M | ||
| Q2 24 | $-8.4M | $47.9M | ||
| Q1 24 | $-133.3M | $15.6M |
| Q4 25 | -7.1% | 147.5% | ||
| Q3 25 | 23.6% | 34.6% | ||
| Q2 25 | 2.5% | 54.7% | ||
| Q1 25 | -32.0% | 19.1% | ||
| Q4 24 | 9.1% | 142.3% | ||
| Q3 24 | — | 60.0% | ||
| Q2 24 | -4.2% | 55.9% | ||
| Q1 24 | -77.3% | 18.7% |
| Q4 25 | 0.1% | 11.5% | ||
| Q3 25 | 0.0% | 3.0% | ||
| Q2 25 | 0.0% | 2.5% | ||
| Q1 25 | 0.0% | 2.1% | ||
| Q4 24 | 0.0% | 10.5% | ||
| Q3 24 | 0.0% | 1.7% | ||
| Q2 24 | 0.0% | 3.8% | ||
| Q1 24 | 0.2% | 2.2% |
| Q4 25 | — | 4.54× | ||
| Q3 25 | 0.50× | 1.05× | ||
| Q2 25 | — | 1.64× | ||
| Q1 25 | — | 0.59× | ||
| Q4 24 | — | 4.51× | ||
| Q3 24 | — | 1.89× | ||
| Q2 24 | — | 1.85× | ||
| Q1 24 | — | 0.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
SYBT
暂无分部数据
